~~<i id='37859F4760'><strike id='37859F4760'><tt id='37859F4760'><pre id='37859F4760'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

author：leisure time 2025-10-02 17:22:42 - browse：76

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Eye stem cell transplant could help restore vision in injured people

focus

leisure time

hotspot

Wikipedia

leisure time

explore

AdobeBiotechstartupReNAgadeTherapeuticsiscuttingstaffjustsevenmonthsafterraisingthelargestSeriesArou

WSS

What to do when lifesaving products contribute to climate change

The EPA's new lead rule: How one expert crunched the numbers

Will the market for weight loss drugs really reach $100 billion?

FDA investigates CAR

What don’t we know about an Alzheimer’s drug side effect?

What don’t we know about an Alzheimer’s drug side effect?

focus

focus

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

U.K. Biobank has 500,000 peoples' genome sequences available

Jerome Adams on the need for new antivirals for Covid

ReNAgade cuts staff seven months after raising $300 million

Virginia high school admissions case could be legal follow

Flagship Pioneering launches a new biotech in two countries

Tori Bowie and the unacceptable rates of Black maternal death

What to do when lifesaving products contribute to climate change

New air purifier tech could be key to improving indoor air quality

Hilary expected to bring catastrophic, life

leisure time

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

As Maui death toll rises, number of missing remains unclear

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Mayo Clinic plans $5B tech

CDC director unscathed in first congressional testimony

hotspot

Wikipedia

leisure time

explore